Pact With NCI Expands Veterans' Access to Trials

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 2
Volume 6
Issue 2

BETHESDA, Md--In a move designed to increase the pool of patients available for clinical trials, the National Cancer Institute has forged an agreement with the Department of Veterans Affairs that will increase the ability of veterans to enroll in phase I, II, and III studies.

BETHESDA, Md--In a move designed to increase the pool of patients availablefor clinical trials, the National Cancer Institute has forged an agreementwith the Department of Veterans Affairs that will increase the abilityof veterans to enroll in phase I, II, and III studies.

Under the agreement, the VA will provide medical coverage for eligibleveterans who participate in NCI-supported studies at non-VA facilities.The pact also envisions that more NCI studies will be conducted in VA hospitalsand clinics.

"Developing an expanded pool of VA cancer researchers will strengthenour clinical research program across the board," said Robert Wittes,MD, director of NCI's Division of Cancer Treatment, Diagnosis, and Centers.

Recent Videos
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
5 experts are featured in this series
2 experts are featured in this series.
5 experts are featured in this series
2 experts are featured in this series.
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
Related Content